

**Anti Tetraneectin (human)  
Mouse Monoclonal Antibody**Subclass: IgG<sub>1</sub>/κ

PRODUCT NO.	<b>HYB 130-13</b>
PRESENTATION	Preparation: Protein-A/G purified Content: 1 ml, 1 mg/mL Solvent: 0.01 M phosphate buffer, pH 7.4, with 0.5 M NaCl and 15mM sodium azide Storage: In the dark at 4-8°C
ANTIGEN	Tetraneectin (TN) is a serum and tissue protein, a C-type lectin, which binds to Ca <sup>++</sup> . It is a homotrimer of monomers each with a mass of 20 kDa, plasma or serum concentrations of TN are found to be approximately 10 mg/l (1,2,4). In vitro, TN can bind to kringle 4 of plasminogen and enhance the activation of plasminogen to plasmin, catalyzed by tissue plasminogen activator in the presence of poly-D-lysine (3). TN is best known as a prognostic marker in ovarian cancer.
IMMUNOGEN	Tetraneectin purified from human citrate plasma (3) and coupled to PPD. Boosted before fusion with recombinant tetraneectin produced in E. coli.
SPECIFICITY	HYB 130-13 is specific for amino acids 17-181 of human tetraneectin monomer
EPITOPE SPECIFICITY	Epitopespecificity is shared with HYB 130-11, as determined by inhibition ELISA (4).
REACTIVITY	HYB 130-13 reacts strongly with tetraneectin. Strong reaction is seen in sandwich ELISA in combination with a polyclonal antibody against tetraneectin (eg. DAKO A0371). In western blotting HYB 130-13 reacts strongly with TN monomer and slightly with TN trimer. In fresh frozen tissues of ovarian cancer, HYB 130-13 shows no staining for TN and no staining of paraffin-embedded, microwave treated tissues. Especially good as both capture and detecting antibody combined with a polyclonal antibody (A371) in sandwich ELISA (4).
CULTURE MEDIUM	Dulbecco's modified Eagle's medium with 10% fetal calf serum
FUSION PARTNER	X63-Ag8.653.
IMMUNIZATION	Female CF1 x BALB/c mice immunized i.p. with immunogen adsorbed onto Al(OH) <sub>3</sub>

## APPLICATION

Method	Usability	Dilution guideline	References
ELISA	Yes	1:8000	4,5
Immunoblotting	Yes		4
Immunohistochemistry	No		4

The dilution guideline for ELISA is based on sandwich ELISA in combination with a polyclonal antibody against the antigen. Users should determine the optimal dilutions for their own purpose.

## REFERENCES

- Holtet TL, Graversen JH, Clemmensen I, Thogersen HC, Etzerodt M (1997) Tetraneectin, a trimeric plasminogen binding C-type lectin. *Protein Sci* 6:1-5.
- Nielsen BB, Kastrup JS, Rasmussen H, Holtet TL, Graversen JH, Etzerodt M, Thogersen HC, Larsen IK (1997) Crystal structure of tetraneectin, a trimeric plasminogen-binding protein with an alpha-helical coiled coil. *FEBS Lett.* 412:388-96.
- Clemmensen I, Petersen LC, Kluff C (1986) Purification and characterization of a novel, oligomeric, plasminogen kringle 4 binding protein from human plasma: Tetraneectin. *Eur J Biochem* 156:327-33.
- Hogdall CK, Christiansen M, Christensen L, Yazova AK, Koch C, Clemmensen I, Norgaard-Pedersen B (1997) Monoclonal antibodies against human tetraneectin, epitope characterization and use in immunohistochemistry. *Clin Chim Acta* 258:159-177.
- Hogdall CK (1998) Human tetraneectin: methodological and clinical studies. *APMIS Suppl* 86:1-31.
- Thougaard AV, Hogdall CK, Kjaer SK, Blaakaer J, Jaliashvili I, Christiansen M (1998) Determination of serum tetraneectin: technical and clinical evaluation of three sandwich immunoassays. *Clin Chim Acta* 276:19-34.
- Thougaard AV, Jaliashvili I, Christiansen M (2001) Tetraneectin-like protein in vertebrate serum: a comparative immunochemical analysis. *Comp Biochem Physiol B Biochem Mol Biol* 128:625-634.
- Westergaard UB, Andersen MH, Heegaard CW, Fedosov SN, Petersen TE (2003) Tetraneectin binds hepatocyte growth factor and tissue-type plasminogen activator. *Eur J Biochem* 270:1850-1854.

## CONDITIONS

All products are supplied on the understanding that they are for in vitro use only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The animals from which this product was derived have not been exposed to or inoculated with any livestock or poultry disease agents exotic to the United States or Western Europe, and did not originate from facilities where work with exotic disease agents affecting livestock or avian species is carried out.